Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Harvard Business School
Mallinckrodt
Colorcon
Dow

Last Updated: November 14, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,759,328

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,759,328 protect, and when does it expire?

Patent 7,759,328 protects SYMBICORT and is included in one NDA.

Protection for SYMBICORT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-five patent family members in twenty-seven countries.

Summary for Patent: 7,759,328
Title:Composition for inhalation
Abstract:The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
Inventor(s): Govind; Nayna (Leicestershire, GB), Marlow; Maria (Leicestershire, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/502,685
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,759,328
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 7,759,328

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-001 Jul 21, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-002 Jul 21, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,759,328

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden0200312Feb 01, 2002
Sweden0200312Feb 1, 2002
PCT Information
PCT FiledJanuary 29, 2003PCT Application Number:PCT/SE03/00156
PCT Publication Date:August 07, 2003PCT Publication Number: WO03/063842

International Family Members for US Patent 7,759,328

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 423552   Start Trial
Austria 463241   Start Trial
Australia 2003206289   Start Trial
Brazil 0307193   Start Trial
Canada 2474479   Start Trial
China 1287774   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
McKinsey
AstraZeneca
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.